Antibiotic

10-Deoxymethymycin is an antibiotic that demonstrates significant antibacterial activity against Gram-positive bacteria. Its mechanism involves inhibition of bacterial protein synthesis, making it a valuable compound for research focused on combating antibiotic-resistant infections. This reagent is suitable for studies on antimicrobial efficacy and resistance mechanisms in bacteria.

Lankamycin is a macrolide antibiotic that exerts its effects through binding to the ribosome exit tunnel, thereby inhibiting protein synthesis in bacteria. It demonstrates moderate antimicrobial activity against various gram-positive bacterial strains. Lankamycin can be utilized in research to explore antibiotic resistance mechanisms and synergistic potential when combined with other antibiotics, such as Lankacidin C.

Parvodicin A is a glycopeptide antibiotic that primarily targets bacterial cell wall synthesis. It demonstrates significant inhibitory activity against Staphylococcus aureus, Staphylococcus furfur, Staphylococcus hemolyticus, and Enterococcus faecalis. This compound is valuable in antimicrobial research and development, particularly in the study of antibiotic resistance and the therapeutic action against multi-drug resistant strains.

2-Hydroxygentamicin A3 is an aminoglycoside antibiotic known for its broad-spectrum activity against both Gram-positive and Gram-negative bacteria. This compound inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, leading to disruptions in cellular processes. It is commonly utilized in research related to microbiology, infectious disease studies, and antibiotic resistance investigations.

1-Deamino-1-hydroxysagamicin is an aminoglycoside antibiotic that exhibits antimicrobial activity against both Gram-positive and Gram-negative bacteria. This compound is utilized in research applications for studying bacterial infections and antibiotic resistance mechanisms. Its broad-spectrum efficacy makes it a valuable tool for exploring the therapeutic potential of antibiotic compounds in microbial research.

Laidlomycin is a polyether antibiotic derived from Streptoverticillium olivoreticuli. It exhibits significant antibacterial activity against a range of Gram-positive bacteria, making it valuable for research in pharmacology and microbiology. Laidlomycin is commonly utilized in studies focused on antibiotic resistance mechanisms and the development of new antimicrobial therapies.

Pyridindolol K1 is an alkaloid antibiotic derived from Streptomyces species K93-0711. This compound exhibits potent antibacterial activity, making it a valuable tool for studying microbial resistance and antibiotic efficacy. Its applications include the exploration of mechanisms of action against Gram-positive and Gram-negative bacteria in various research settings.

N-(3-Oxobutanoyl)-L-homoserine lactone is an antibiotic autoregulator that plays a critical role in the biosynthesis of carbapenem antibiotics in Erwinia carotovora ATCC 39048. This compound is known to induce the expression of the rhiI gene in R. leguminosarum, highlighting its importance in bacterial communication and regulation. It is valuable for research on quorum sensing and antibiotic production pathways.

Polymyxin D1 is a heteropeptide antibiotic targeting the outer membrane of Gram-negative bacteria. It exhibits potent antibacterial activity, making it particularly effective against various strains of Gram-negative pathogens. This compound holds significant potential for research applications in the study of antibiotic resistance and the development of new therapeutic strategies against multidrug-resistant bacterial infections.

Monensin C is an oxygen-containing heterocyclic polyether antibiotic that primarily targets various microbial pathogens. It exhibits antibacterial, mycobacterial, antifungal, and protozoan activities. Notably, Monensin C has a reduced effectiveness against Gram-negative bacteria and demonstrates an inhibitory effect on HeLa cells. This compound is useful for research applications focusing on microbial resistance mechanisms and cellular responses to antibiotic treatments.

Mycinamicin VI is a macrolide antibiotic that primarily targets bacterial protein synthesis. It exhibits potent activity against Gram-positive bacteria, making it a valuable reagent for research into antimicrobial mechanisms and drug resistance. Mycinamicin VI is useful for studies focusing on bacterial infections and the development of novel antibacterial therapies.

Lankacyclinol A is an orally active antibiotic derived from Streptomyces rochei, demonstrating broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative bacteria. This compound shows low toxicity in murine models, making it a promising candidate for further research in infectious disease treatment and antibiotic development.

Raja 42 is a gamma lactam antibiotic that targets bacterial cell wall synthesis. It exhibits broad-spectrum efficacy against both Gram-positive and Gram-negative bacteria, including strains of Clostridium difficile. This compound is useful in microbiological research and antibiotic susceptibility studies.

Aerocyanidin is an antibiotic characterized by its isonitrile group, demonstrating potent activity against Gram-positive bacteria. Its mechanism of action involves inhibiting bacterial cell wall synthesis, making it a valuable tool in the study of bacterial resistance and the development of new antibacterial therapies. Research applications include investigating the efficacy of antibiotics and exploring bacterial susceptibility profiles.

Pluracidomycin C1 is a carbapenem antibiotic that exhibits potent antibacterial activity against both Gram-positive and Gram-negative bacteria. Its primary mechanism involves the inhibition of β-lactamase enzymes, enhancing its effectiveness against resistant strains. This compound is valuable for research applications focusing on antibiotic resistance and the development of new antimicrobial therapies.

Germicidin B is an antibiotic that exhibits bactericidal activity through the inhibition of hexokinase II, with an IC50 of 25.16 μM. It effectively suppresses spore germination in Streptomyces. Germicidin B is suitable for research applications focused on bacterial infections and antibiotic mechanisms.

Aplasmomycin is a boron-containing macrodiolide antibiotic targeting Gram-positive bacteria. It demonstrates potent antimicrobial activity and has been shown to inhibit plasmodium infections in vivo. This compound is useful in research applications focused on antibacterial and antimalarial effects, contributing to the understanding of microbial resistance and potential therapeutic strategies.

5-Hydroxymethyltubercidin, a semi-synthetic antibiotic derived from tuberculin-5-carboxylic acid, exhibits potent antibacterial activity. This compound is utilized in research to investigate mechanisms of antibiotic action and resistance, particularly in the context of bacterial infections. Its unique structure allows for the exploration of new therapeutic strategies against drug-resistant pathogens.

Exfoliamycin is a naphthoquinone antibiotic that exerts its antibacterial effects primarily against Gram-positive bacteria. Isolated from the actinobacterium Streptomyces Exfoliamycin Tu 1424, this compound has shown potential in various research applications, particularly in the study of bacterial resistance and antibiotic development. Its unique mechanism of action offers insights into antimicrobial strategies and therapeutic interventions.

Pneumocandin A1 is a lipopeptide antibiotic that specifically targets Candida species by inhibiting the synthesis of 1,3-β-D-glucan, a critical component of fungal cell walls. With an IC50 value of 0.07-0.5 μg/mL, it demonstrates potent antifungal activity in vitro. Pneumocandin A1 is primarily utilized in research applications focused on antifungal drug development and the study of fungal pathogenesis.

Bekanamycin sulfate is an aminoglycoside antibiotic with a primary mechanism of action targeting bacterial ribosomes, thereby inhibiting protein synthesis. As a minor component of the kanamycin complex, it exhibits significant antibacterial activity against a range of Gram-negative and some Gram-positive bacteria. This reagent is utilized in microbiological research and can be employed in studies assessing bacterial resistance and efficacy of antibiotic treatments.

Hongoquercin B is a sesquiterpene antibiotic with demonstrated activity against Vancomycin-resistant Enterococcus faecium, exhibiting its effects primarily at elevated concentrations. This compound is valuable for studying antibiotic resistance mechanisms and the development of novel antimicrobial strategies. Its specific interaction profiles make it a candidate for further exploration in antibiotic research and therapeutic applications.

A-25794 is an antibiotic that exhibits notable antidepressant properties. Primarily targeting bacterial infections, it has been identified for its potential effects on mood regulation. This compound may serve as a valuable tool in research focused on the intersection of antimicrobial treatments and mental health therapeutics.

Mycoplanecin A is a cyclic peptide antibiotic that primarily targets mycobacterial infections. It exhibits potent anti-mycobacterial activity, along with significant effects against Luteus and Hypococcus species. Additionally, Mycoplanecin A demonstrates moderate antibacterial efficacy against Xanthomonas oryzae and various strains of Actinomycetes, making it a valuable reagent for research in antibiotic resistance and microbial pathogenesis.

Leucomycin A4 is a macrolide antibiotic derived from Streptomyces kitasatoensis. It exhibits potent antibacterial activity against a range of pathogens, including Staphylococcus aureus, Bacillus subtilis, Corynebacterium diphtheriae, Neisseria gonorrhoeae, and Haemophilus influenzae, with minimum inhibitory concentrations (MICs) of 0.15, 1.25, 0.15, 0.6, and 0.15 µg/ml, respectively. Leucomycin A4 is utilized in microbial research and drug development as a crucial tool for studying antibiotic resistance and bacterial infections.

Aibellin is a peptide antibiotic that exerts its primary action by modifying rumen fermentation processes. This compound is recognized for its ability to enhance microbial efficiency and nutrient absorption in ruminant livestock. Aibellin has significant implications in agricultural research, particularly in improving feed conversion and overall animal health.

Monamycin B is an ester peptide antibiotic targeting Gram-positive bacteria. This compound exhibits effective antibacterial properties, making it suitable for research applications related to microbial resistance and the development of new antimicrobial agents. Its unique mechanism of action contributes to its potential use in studying bacterial pathogenesis and antibiotic efficacy.

ME-1036 is a carbapenem antibiotic that exhibits potent activity against resistant Gram-positive organisms, including Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). Additionally, it demonstrates efficacy against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae. However, ME-1036 is not effective against Pseudomonas aeruginosa. This compound is valuable for research focused on antibiotic resistance and the development of novel therapeutic strategies.

Defucogilvocarcin V is a gilvocarcin antibiotic that primarily targets Gram-positive bacteria. It exhibits potent antibacterial activity, making it a valuable reagent for research focused on microbial infections. Its unique mechanism can be leveraged in studies exploring antibiotic resistance and the development of new therapeutic strategies.

Cinnabarin is an antibiotic extracted from the fungi Polystiotus cinnabarinus, P. versicolo, and Trametes cinnabarinus. It demonstrates antibacterial activity specifically against Gram-positive bacteria and possesses notable antiviral properties. This compound serves as a valuable tool in infectious disease research, offering insights into potential therapeutic applications and mechanisms of action.

2-Hydroxybutirosin is an antibiotic that inhibits bacterial protein synthesis, primarily targeting the ribosomal 50S subunit. Isolated from Bacillus circulans, it exhibits notable antibacterial activity against a spectrum of gram-positive bacteria. This compound is valuable for research in antibiotic resistance mechanisms and the development of novel antibacterial agents.

DQ 2556 is a semi-synthetic cephalosporin antibiotic that targets penicillin-binding proteins (PBPs). It exhibits notable bactericidal activity against both Gram-positive and Gram-negative bacteria, with particularly strong efficacy against Gram-positive strains and Enterobacteriaceae infections. By disrupting cell division, DQ 2556 demonstrates significant in vivo protective effects. This compound is valuable in the research and development of injectable cephalosporin formulations.

Gunacin is a quinone antibiotic that targets a broad spectrum of bacteria. It exhibits potent antibacterial activity against Gram-positive and Gram-negative bacteria, as well as mycoplasma. This compound is utilized in research applications aimed at understanding bacterial resistance mechanisms and exploring new therapeutic options.

Epoxyquinomicin B is an antibiotic sourced from Amycolatopsis sp., primarily targeting bacterial pathogens. It demonstrates significant inhibitory activity against Micrococcus luteus, Bacillus subtilis, Pasteurella piscicida, and Staphylococcus aureus, with a minimum inhibitory concentration (MIC) ranging from 6.25 to 12.5 µg/mL. Additionally, Epoxyquinomicin B exhibits cytotoxic effects in L1210 cancer cells, with an IC50 of 16.3 µg/mL, and shows potential anti-inflammatory properties in models of collagen-induced arthritis. Its diverse biological activities render it a valuable tool for research in microbiology and cancer therapeutics.

Monamycin F is an ester peptide antibiotic primarily targeting Gram-positive bacteria. It demonstrates significant antibacterial activity, making it a valuable tool for research in microbiology and antibiotic development. This compound is useful for studying bacterial resistance mechanisms and evaluating the efficacy of antibiotic therapies.

Oximidine III is an antitumor antibiotic that selectively inhibits the growth of 3Y1 rat fibroblast cells, demonstrating significant effects on various tumor-associated genes. It targets both v-H-ras-3Y1 and v-src-3Y1 cells, with IC50 values of 14 nM and 4.5 nM, respectively, while normal 3Y1 cells show an IC50 of 140 nM. Oximidine III effectively halts the cell cycle at the G1 phase in RAS or SRC-activated cells and promotes the expression of p21WAF1, making it valuable for research in cancer biology and therapeutic development.

A 53868A is an antibiotic derived from Streptomyces luridus, specifically targeting bacterial cell wall synthesis. This compound exhibits potent antimicrobial activity, making it suitable for research applications in microbiology, drug resistance studies, and the exploration of new therapeutic agents against bacterial infections.

Hatomamicin is an alkaloid antibiotic with potent activity against Gram-positive bacteria. Isolated from the culture filtrate of Sucrose Polyspora, it serves as a valuable tool in antibacterial research. Its mechanism of action and biological activity make it relevant for studies focused on developing new antimicrobial therapies.

Deflectin 1a is an antibiotic that primarily targets bacterial cells, demonstrating the ability to lyse both bacteria and red blood cells. Additionally, it exhibits inhibitory effects on Ehrlich ascites cancer cells, making it a valuable tool in cancer research. Notably, its activity can be modulated by the presence of serum or serum albumin, providing insights into its mechanism and potential applications in various biological studies.

Nortopixantrone dihydrochloride is a 9-aza-anthrapyrazole-based antineoplastic antibiotic that targets cancer cell proliferation. It exhibits significant cytotoxic activity against a variety of tumor cell lines, making it a valuable tool in cancer research. This compound is utilized in studies aimed at understanding its mechanisms of action and potential therapeutic applications in oncology.

Demethylolivomycin B is an antitumor antibiotic that primarily targets bacterial and cancerous cells. It exhibits modest activity against Gram-positive bacteria and demonstrates potential therapeutic effects in tumor models. This compound is relevant for research focused on antibiotic resistance and cancer treatment strategies.

Mureidomycin B is an antibiotic that targets Pseudomonas aeruginosa, exhibiting potent antibacterial activity against this pathogen. It is primarily utilized in research related to bacterial infections and the development of antibiotic resistance. This compound can serve as a valuable tool in exploring therapeutic options for infections caused by multidrug-resistant strains.

Bis(N-methylthioformohydroxamate)nickel (II) acts as an antitumor antibiotic, leveraging the properties of metallic nickel. This compound exhibits significant antimicrobial activity against both Gram-positive and Gram-negative bacteria while demonstrating potent antitumor effects. It is valuable for research in oncology and microbiology, providing insights into therapeutic applications and mechanisms of action against resistant pathogens.

Pyralomicin 1d is an antibiotic that exhibits potent antibacterial activity by targeting bacterial ribosomes, thereby inhibiting protein synthesis. This compound is valuable for research applications focused on understanding bacterial resistance mechanisms and developing new antimicrobial therapies. Its efficacy against various Gram-positive and Gram-negative bacteria makes it a pertinent tool in microbiological studies and antibiotic development.

Griseorhodin A is a quinone antibiotic that primarily targets Gram-positive bacteria. This compound exhibits significant antibacterial activity, making it valuable for research focusing on bacterial infections and resistance mechanisms. Its distinctive mechanism of action contributes to the exploration of novel therapeutic strategies against resistant bacterial strains.

Resorthiomycin is an antitumor antibiotic known for its ability to inhibit leukemia cell lines, specifically L5178Y, in vitro. This compound demonstrates significant cytotoxic activity, making it a valuable tool in cancer research. Its mechanisms of action offer insights into the potential therapeutic applications in combating hematological malignancies.

Pyrazomycin II, an antibiotic, functions as a competitive inhibitor of pyrimidine nucleoside metabolism. Its primary biological activity demonstrates efficacy against various bacterial strains, making it a valuable tool in antibiotic research. Pyrazomycin II can be utilized in studies focused on antibacterial mechanisms and the development of new therapeutic strategies for bacterial infections.

Polymyxin M is a cyclic peptide antibiotic that targets the outer membrane of Gram-negative bacteria. It disrupts bacterial cell membrane integrity, leading to cell lysis and death. Polymyxin M is primarily utilized in research focusing on antibiotic resistance and the mechanisms of bacterial infection. Its effectiveness against multidrug-resistant pathogens makes it a valuable tool for studies in microbiology and infectious disease.

Maridomycin VI is a macrolide antibiotic that primarily targets Gram-positive bacteria and mycoplasma. It demonstrates significant antibacterial activity and has been shown to provide protective effects in murine models of Gram-positive bacterial infections. This compound is potentially useful for research applications focused on bacterial resistance and antibiotic efficacy.

Mirosamicin is a potent antibiotic that exhibits significant antibacterial activity against a broad spectrum of gram-positive bacteria, select gram-negative bacteria, and mycoplasma. Its efficacy makes it a valuable reagent for research in food safety monitoring and microbial resistance studies.